E Kay1, A O'Grady, J M Morgan, S Wozniak, B Jasani. 1. Department of Pathology, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin 9, Ireland. mleader@iol.ie
Abstract
AIMS: To evaluate the use of tissue microarray (TMA) technology as a validation tool for HER2 testing by both immunocytochemistry (ICC) and fluorescence in situ hybridisation (FISH) in the diagnostic setting. METHODS: TMA constructs from 57 cases of breast cancer were evaluated for HER2 (by ICC and FISH) by two centres. The results were compared. RESULTS: There was a high level of concordance for both ICC and FISH. In five "discrepant" cases only three would have had a potential impact on patient management. CONCLUSIONS: Validation of HER2 analysis in the clinical setting by ICC and FISH is essential. The use of TMAs provides for an economy of scale and would be practical in the setting of interlaboratory and intralaboratory validation. It is suggested that routine HER2 ICC and FISH should continue to be performed in laboratories on whole sections. Following this, TMAs would be constructed for all cases of breast cancer. ICC and FISH would be performed on these to validate the results. The TMAs would be available for circulation to other centres for validation purposes. The standardisation of testing between centres, the potential difficulty of minimum case numbers, and the workload issues surrounding validation would all be facilitated by this approach.
AIMS: To evaluate the use of tissue microarray (TMA) technology as a validation tool for HER2 testing by both immunocytochemistry (ICC) and fluorescence in situ hybridisation (FISH) in the diagnostic setting. METHODS:TMA constructs from 57 cases of breast cancer were evaluated for HER2 (by ICC and FISH) by two centres. The results were compared. RESULTS: There was a high level of concordance for both ICC and FISH. In five "discrepant" cases only three would have had a potential impact on patient management. CONCLUSIONS: Validation of HER2 analysis in the clinical setting by ICC and FISH is essential. The use of TMAs provides for an economy of scale and would be practical in the setting of interlaboratory and intralaboratory validation. It is suggested that routine HER2 ICC and FISH should continue to be performed in laboratories on whole sections. Following this, TMAs would be constructed for all cases of breast cancer. ICC and FISH would be performed on these to validate the results. The TMAs would be available for circulation to other centres for validation purposes. The standardisation of testing between centres, the potential difficulty of minimum case numbers, and the workload issues surrounding validation would all be facilitated by this approach.
Authors: I O Ellis; J Bartlett; M Dowsett; S Humphreys; B Jasani; K Miller; S E Pinder; A Rhodes; R Walker Journal: J Clin Pathol Date: 2004-03 Impact factor: 3.411
Authors: A Hoos; M J Urist; A Stojadinovic; S Mastorides; M E Dudas; D H Leung; D Kuo; M F Brennan; J J Lewis; C Cordon-Cardo Journal: Am J Pathol Date: 2001-04 Impact factor: 4.307
Authors: Anthony Rhodes; Bharat Jasani; Jérĵme Couturier; Mark J McKinley; John M Morgan; Andrew R Dodson; Hossein Navabi; Keith D Miller; André J Balaton Journal: Am J Clin Pathol Date: 2002-01 Impact factor: 2.493
Authors: I O Ellis; M Dowsett; J Bartlett; R Walker; T Cooke; W Gullick; B Gusterson; E Mallon; P B Lee Journal: J Clin Pathol Date: 2000-12 Impact factor: 3.411
Authors: Soonmyung Paik; John Bryant; Elizabeth Tan-Chiu; Edward Romond; William Hiller; Kyeongmee Park; Ann Brown; Greg Yothers; Steve Anderson; Roy Smith; D Lawrence Wickerham; Norman Wolmark Journal: J Natl Cancer Inst Date: 2002-06-05 Impact factor: 13.506
Authors: J Kononen; L Bubendorf; A Kallioniemi; M Bärlund; P Schraml; S Leighton; J Torhorst; M J Mihatsch; G Sauter; O P Kallioniemi Journal: Nat Med Date: 1998-07 Impact factor: 53.440
Authors: Jennifer Bordeaux; Allison Welsh; Seema Agarwal; Elizabeth Killiam; Maria Baquero; Jason Hanna; Valsamo Anagnostou; David Rimm Journal: Biotechniques Date: 2010-03 Impact factor: 1.993
Authors: Katrine L Henriksen; Birgitte B Rasmussen; Anne E Lykkesfeldt; Susann Møller; Bent Ejlertsen; Henning T Mouridsen Journal: J Clin Pathol Date: 2006-06-14 Impact factor: 3.411
Authors: Angela P Presson; Nam K Yoon; Lora Bagryanova; Vei Mah; Mohammad Alavi; Erin L Maresh; Ayyappan K Rajasekaran; Lee Goodglick; David Chia; Steve Horvath Journal: BMC Cancer Date: 2011-06-08 Impact factor: 4.430
Authors: Seán Fitzgerald; Katherine M Sheehan; Virginia Espina; Anthony O'Grady; Robert Cummins; Dermot Kenny; Lance Liotta; Richard O'Kennedy; Elaine W Kay; Gregor S Kijanka Journal: J Pathol Clin Res Date: 2014-11-17
Authors: Muireann T Kelleher; Gilbert Fruhwirth; Gargi Patel; Enyinnaya Ofo; Frederic Festy; Paul R Barber; Simon M Ameer-Beg; Borivoj Vojnovic; Cheryl Gillett; Anthony Coolen; György Kéri; Paul A Ellis; Tony Ng Journal: Target Oncol Date: 2009-09-16 Impact factor: 4.493